Skip to content

D&A at other companies

Pfizer logo
PfizerPFE
$1.61B-0.3%
Amgen logo
AmgenAMGN
$1.12B-19.5%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$130K-11.0%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$121K+3.4%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$5.92M+34.2%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$439K-8.0%

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's D&A?
Zymeworks (ZYME) reported D&A of $963K in Q1 2026.
How has Zymeworks's D&A changed year-over-year?
Zymeworks's D&A decreased by 1.8% year-over-year, from $981K to $963K.
What is the long-term trend for Zymeworks's D&A?
Over 4 years (2021 to 2025), Zymeworks's D&A has grown at a -0.5% compound annual growth rate (CAGR), from $3.74M to $3.67M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.